Gross Margin

A $25M payment from partner Chiesi catapults Protalix to a profitable quarter, funding a promising new gout therapy and a broader rare disease strategy.

As Quebecor prepares for its annual meeting, a look at its strong 2025 results, aggressive telecom expansion, and strategy to challenge Canada's giants.

The nation's largest EMS provider, GMR Solutions, saw its stock surge on its NYSE debut after a major IPO price cut to appease wary investors.

JBS posts a $221M profit despite a major loss in its US beef unit, showcasing the power of its diversified global strategy in volatile markets.

The industrial giant affirms its quarterly payout, a sign of stability for investors as it navigates a costly green transition and recent regulatory hurdles.

As BranchOut Food preps its Q1 earnings call, investors watch to see if its patented tech and retail wins can deliver on the path to profitability.

The cell-engineering firm posted a smaller-than-expected loss and announced a share buyback, signaling confidence despite a dip in core Q1 revenue.

Resideo posted strong Q1 results with an 8% revenue jump to $1.91B, setting a positive stage for the planned separation of its ADI distribution arm.

Amid a surging lithium market, Lithium Argentina posts stellar Q1 results, using its operational prowess to fund ambitious expansion projects in Argentina.

The medtech firm reports a 19% revenue surge and a return to profitability, validating its new pure-play strategy focused on the surgical market.

A massive acquisition and a surge in urea prices propelled Adecoagro to a record quarter, offsetting commodity slumps and redefining its future.

Backed by Dongfeng and already profitable, Chinese EV brand VOYAH is charting a unique global path with production-ready tech and a disciplined strategy.

Formula 1 meets pet couture as VETRESKA partners with Ollie Bearman, signaling a new era of lifestyle brand sponsorships in high-speed motorsport.

The specialty manufacturer reports a 46% profit surge, fueled by strong demand for its key drug and a major distributor's comeback. What's next?

The federal tech firm posts a 23% revenue jump, eliminates debt, and builds a record backlog, signaling a new phase of strategic growth.

The service commerce platform saw net income jump over 700% despite a drop in adjusted EBITDA, signaling a massive strategic bet on its AI-driven future.

The environmental services firm posted sequential growth and cut costs, signaling a strategic pivot despite a year-over-year revenue dip.

The cloud company's results show modest growth, but a strategic pivot to shed a recent acquisition and focus on its 'Dash' AI tool is paying off.

The chipmaker topped Q1 estimates and eyes a strong Q2, fueled by EV and AI markets, even as restructuring charges weigh on its bottom line.

Artivion posts strong Q1 results and acquires Endospan for its FDA-approved NEXUS system, yet lowers its full-year guidance. What's behind the mixed message?